<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680183</url>
  </required_header>
  <id_info>
    <org_study_id>PTKI-HBV-01</org_study_id>
    <nct_id>NCT03680183</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)</brief_title>
  <official_title>Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors in Chinese Patients of Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will explore the characteristics in clinical pharmacokinetics of gefitinib,
      erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of
      Non-small-cell lung cancer and hepatitis B. The study is self-controlled. The plasma
      concentration of tyrosine kinase inhibitors will be analyzed before and after system
      treatment of HBV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tyrosine kinase inhibitors (TKIs) are first line treatment for non-small-cell lung cancer
      patients with mutations in targeted genes. TKIs are metabolized in liver into inactive
      metabolites before eliminating from body. Liver function might plays a significant role in
      inter-individual differences of pharmacokinetics of TKIs. Hepatitis B is a disease of high
      prevalence in south China. The liver function will be compromised if the infection of
      hepatitis B virus has not been controlled. This study aims to compare the pharmacokinetics of
      TKIs before and after controlling HBV with standard treatment in Chinese patients of
      non-small-cell lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Average plasma concentration of the drugs (TKIs)</measure>
    <time_frame>one year after recruit</time_frame>
    <description>compare the concentration of TKIs prior to and after anti-HBV treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reaction caused by TKIs</measure>
    <time_frame>one year after recruit</time_frame>
    <description>the adverse reaction of TKIs before and after anti-HBV treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Pre-exposure</arm_group_label>
    <description>Entecavir 1Mg Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-exposure</arm_group_label>
    <description>Entecavir 1Mg Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir 1Mg Oral Tablet</intervention_name>
    <description>The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)</description>
    <arm_group_label>Post-exposure</arm_group_label>
    <arm_group_label>Pre-exposure</arm_group_label>
    <other_name>Bicyclol Tablets</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5ml of whole blood is collected before and after the anti-HBV treatment to measure the plasma
      concentration of TKIs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients diagnosed of non-small-cell lung cancer. Controlled group are HBV negative
        and HBV group are diagnosed of chronic hepatitis B. All subjects should be able to make
        their own decision and sign informed concerned.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological confirmed non-small-cell lung cancer

          -  with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)
             genetic mutation required by different TKIs

          -  liver function, ALT and/or AST &lt;= 2*upper limit of normal (ULN)

          -  diagnosed of chronic hepatitis B

          -  Hepatitis B negative as controlled group

          -  receiving one type of TKIs

          -  Age between 18-70

        Exclusion Criteria:

          -  diagnosed of acute/ active hepatitis B

          -  diagnosed of AIDS

          -  unable to make decision because of metastasis to central nervous system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuzhong Cui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenying Shu, PhD</last_name>
    <phone>86-20-66673666</phone>
    <phone_ext>2006</phone_ext>
    <email>790840799@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510182</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenying Shu, PhD</last_name>
      <phone>86-20-66673666</phone>
      <phone_ext>2006</phone_ext>
      <email>790840799@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Tiantian Cheng, MD</last_name>
      <phone>86-20-66673677</phone>
      <email>gyzlgcp@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Tian-Tian Cheng</investigator_full_name>
    <investigator_title>Secretary of GCP</investigator_title>
  </responsible_party>
  <keyword>Tyrosine kinase inhibitors</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

